Jefferies Financial Group Inc. Buys Shares of 22,000 Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)

Jefferies Financial Group Inc. purchased a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 22,000 shares of the company’s stock, valued at approximately $91,000.

Other large investors also recently modified their holdings of the company. Inspire Investing LLC bought a new position in Eledon Pharmaceuticals in the fourth quarter valued at about $802,000. Charles Schwab Investment Management Inc. grew its stake in shares of Eledon Pharmaceuticals by 100.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 29,987 shares of the company’s stock valued at $124,000 after purchasing an additional 15,000 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Eledon Pharmaceuticals by 418.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock valued at $33,000 after purchasing an additional 6,412 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Eledon Pharmaceuticals by 75.4% during the 4th quarter. Geode Capital Management LLC now owns 663,101 shares of the company’s stock valued at $2,733,000 after purchasing an additional 285,043 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Eledon Pharmaceuticals in the 4th quarter worth approximately $82,000. Institutional investors own 56.77% of the company’s stock.

Eledon Pharmaceuticals Stock Performance

Shares of Eledon Pharmaceuticals stock opened at $2.87 on Monday. The stock has a market cap of $171.86 million, a P/E ratio of -1.43 and a beta of 0.08. The stock’s fifty day moving average is $3.17 and its 200 day moving average is $3.94. Eledon Pharmaceuticals, Inc. has a one year low of $2.30 and a one year high of $5.54.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.20. Analysts predict that Eledon Pharmaceuticals, Inc. will post -0.81 EPS for the current year.

Analysts Set New Price Targets

Separately, Guggenheim began coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They set a “buy” rating and a $9.00 target price for the company.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).